Download PDF
Thromb Haemost 1985; 53(03): 306-311
DOI: 10.1055/s-0038-1661303
Original Article
Schattauer GmbH Stuttgart

Endothelial Cells Produce a Lipoxygenase Derived Chemo-Repellent which Influences Platelet/Endothelial Cell Interactions – Effect of Aspirin and Salicylate[*]

M R Buchanan
The Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
R W Butt
The Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
Z Magas
The Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
J Van Ryn
The Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
J Hirsh
The Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
D J Nazir
The Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 24 October 1984

Accepted 12 February 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We performed experiments to determine whether endothelial cells synthesize phospholipid metabolites via the lipoxygenase pathway and whether these metabolites influence platelet/vessel wall interactions. Monolayers of cultured human endothelial cells were incubated with 14C-arachidonic acid and their cyclo-oxygenase and lipoxygenase metabolites were extracted and identified by radioimmunoassay, thin layer chromatography and high performance liquid chromatography. We found that in addition to the membrane-associated production of PGI2, endothelial cells synthesized a cytosol-associated metabolite, LOX, which was presumably derived through the lipoxygenase pathway. Inhibition of LOX was associated with an increase in PGI2 production and inhibition of PGI2 with an increase in LOX production. Under either condition, platelet adhesion to cultured endothelial cells was significantly decreased. In contrast, when both PGI2 and LOX production were inhibited, platelet adhesion to endothelial cells was enhanced. Furthermore, when LOX was bound to a thrombogenic surface, platelet adhesion was significantly decreased whereas when arachidonic acid or 12-HETE was bound to the surface, platelet adhesion was increased. We conclude that endothelial cells produce not only a cyclo-oxygenase metabolite, but also a lipoxygenase metabolite, both of which influence platelet/endothelial cell interactions.

Keywords

Endothelial cell - Lipoxygenase metabolite LOX - Platelet chemo-repellent factor

Presented, in part, in abstract form at the IXth International Congress Society on Thrombosis and Haemostasis in Stockholm, Sweden, July, 1983.


 

  • References

  • 1 Hamberg M, Samuelsson B. Prostaglandin endoperoxidases. Novel transformations of arachidonic acid in human platelets Proc Natl Acad Sci USA 1974; 71: 3400-3404
    CrossrefPubMedGoogle Scholar
  • 2 Hammarstrom S, Falardeau P. Resolution of prostaglandin endoperoxide synthetase and thromboxane synthetase of human platelets. Proc Natl Acad Sci USA 1977; 74: 3691-3695
    CrossrefPubMedGoogle Scholar
  • 3 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300: 1142-1147
    CrossrefPubMedGoogle Scholar
  • 4 Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium Thromb Res 1977; 11: 323-344
    CrossrefPubMedGoogle Scholar
  • 5 Buchanan MR, Dejana E, Gent M, Mustard JF, Hirsh J. Enhanced platelet accumulation onto injured carotid arteries in rabbits following aspirin treatment. J Clin Invest 1981; 67: 503-508
    CrossrefPubMedGoogle Scholar
  • 6 Kelton JG, Hirsh J, Carter CJ, Buchanan MR. Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity J Clin Invest 1978; 62: 892-895
    CrossrefPubMedGoogle Scholar
  • 7 Buchanan MR, Hirsh J. The effect of aspirin and salicylate on platelet/vessel wall interactions in rabbits. Atherosclerosis 1984; 4: 403-406
    PubMedGoogle Scholar
  • 8 Buchanan MR, Butt RW, Nazir D, Turpie AG G, Hirsh J. The regulation of platelet/endothelial cell adhesion by two arachidonic acid metabolites. Thromb Haemostas 1983; 50: 190 (Abstr.)
    PubMedGoogle Scholar
  • 9 Bailey JM, Bryant RW, Feinmark SJ, Makheja AN. Differential separation of thromboxanes from prostaglandins by one and twodimensional thin layer chromatography. Prostaglandins 1977; 13: 479-492
    CrossrefPubMedGoogle Scholar
  • 10 Buchanan MR, Blajchman MA, Dejana E, Mustard JF, Senyi AF, Hirsh J. Shortening of the bleeding time in thrombocytopenic rabbits after exposure of jugular vein to high aspirin concentrations. Prostaglandins Med 1979; 13: 333-342
    PubMedGoogle Scholar
  • 11 Kinlough-Rathbone RL, Mustard JF, Packham MA, Perry DW, Reimers H-J, Cazenave J-P. Properties of washed human platelets. Thromb Haemostas 1977; 37: 291-308
    PubMedGoogle Scholar
  • 12 Gimbrone MA, Buchanan MR. Interactions of platelets and leukocytes with vascular endothelium: In vitro studies. In Endothelium Fishmann AP. (Ed) Ann NY Acad Sci 1983; 401: 171-183
    PubMedGoogle Scholar
  • 13 Buchanan MR, Butt RW, Markham B, Hirsh J. Effects of aspirin and salicylate on platelet function. Thromb Haemostas 1983; 50: 101
    PubMedGoogle Scholar
  • 14 Gimbrone MA, Shefton ES, Cruise SA. Isolation and primary culture of endothelial cells from human umbilical vessels. TCA Manual 1978; 4: 813-817
    CrossrefPubMedGoogle Scholar
  • 15 Buchanan MR, Rischke JA, Butt RW, Turpie AG G, Hirsh J, Rosenfeld J. The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thromb Res 1983; 29: 125-139
    CrossrefPubMedGoogle Scholar
  • 16 Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 1982; 306: 381-386
    CrossrefPubMedGoogle Scholar
  • 17 Roth GJ, Majerus PW. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632
    CrossrefPubMedGoogle Scholar
  • 18 Siegel MI, McConnell RT, Cuatrecasas P. Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc Natl Acad Sci USA 1979; 76: 3774-3778
    CrossrefPubMedGoogle Scholar
  • 19 Wilhelm TE, Sankarappa SK, Van Rollins M, Sprecher H. Selective inhibitors of platelet lipoxygenase: 4,7,10,13-icosatetraynoic acid and 5,8,11,14-henicosatetraynoic acid. Prostaglandins 1981; 21: 323-332
    CrossrefPubMedGoogle Scholar
  • 20 Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. Amer Statist Assoc J 1955; 50: 1096-1106
    PubMedGoogle Scholar
  • 21 Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964; 20: 482-491
    CrossrefPubMedGoogle Scholar
  • 22 Sawyer PN, Srinivasan S. The role of electrochemical surface properties in thrombosis at vascular interfaces: cumulative experience of studies in animals and man. Bull NY Acad Med 1972; 48: 235-256
    PubMedGoogle Scholar
  • 23 Hammarstrom S. Leukotrienes: cellular regulators formed by conjugation of polyunsaturated fatty acids with glutathione. In Reviews in Biochemical Toxicology. Hodgson E, Benel JR, Philpot RM. (Eds) Elsevier Science Publishing Co Inc: New York, New York: 1983. p 173
    Google Scholar
  • 24 Nugteren DH. Arachidonate lipoxygenase in blood platelets. Biochim Biophys Acta 1975; 380: 299-307
    CrossrefPubMedGoogle Scholar
  • 25 Smith JB. Prostaglandins and platelet aggregation. Acta Med Scand 1981; (Suppl) (Suppl. 210) 651: 91-99
    PubMedGoogle Scholar
  • 26 Malmsten CL. The effects of some non-steroidal anti-inflammatory drugs upon LTB4 formation and granulocyte function in vitro. In Prostaglandins and Leukotrienes ’84. Abst Vol. Bailey JM. (Ed) George Washington Univ Press; Washington D C: 1984. p 15
    Google Scholar
  • 27 Gorman RR. Modulation of human platelet function by prostacyclin and thromboxane A2 . Fed Proc 1979; 38: 83-88
    PubMedGoogle Scholar